Wayne Kuznar

Articles

Brentuximab Vedotin Shows Activity in B-Cell Lymphomas

December 12th 2013

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC

December 12th 2013

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

December 12th 2013

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Ofatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLL

December 10th 2013

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

Ibrutinib Induces Rapid, Durable Responses in WaldenstrÃ¶m's Macroglobulinemia

December 9th 2013

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory WaldenstrÃ¶m's macroglobulinemia, and the responses to ibrutinib were durable.

Bcl-2 Inhibitor ABT-199 Shows Promise in CLL and SLL

December 9th 2013

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma

December 9th 2013

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Longer Bortezomib Duration Linked to Improved Survival in Multiple Myeloma

December 8th 2013

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Similar Benefit, Lower Toxicity Found With Capecitabine- Versus Gemcitabine-based Chemoradiation in Pancreatic Cancer

March 6th 2013

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Complete Neoadjuvant Chemotherapy May Offer New Framework for Treating Rectal Cancer

March 4th 2013

Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.

PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC

February 16th 2013

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

No Survival Advantage for Tivozanib Over Sorafenib in TIVO-1 Study

February 16th 2013

Tivozanib did not show a significant difference in overall survival when compared with sorafenib in patients with renal cell carcinoma who received up to one prior line of therapy excluding targeted agents.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Nab-Paclitaxel Plus Gemcitabine Could Be New 'Backbone' of Therapy for Metastatic Pancreatic Cancer

January 28th 2013

Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.

Ramucirumab Moderately Boosts Survival in Advanced Gastric Cancer

January 28th 2013

Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.

Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer

January 28th 2013

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.